forgot about reovirus. Here are some trials:
http://www.oncolyticsbiotech.com/clinical.html
Oncolytics Biotech is directing a broad clinical trial program with the objective of developing REOLYSIN® as a human cancer therapeutic. The current clinical program includes human trials using REOLYSIN® alone and in combination with chemotherapy or immune modulation, and delivered via local administration and/or intravenous administration. The Company's first pivotal trial will be a Phase III randomized clinical trial examining the intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with platinum-failed head and neck cancers.
Clinical Trial Chart
Click on clinical trial for more detailed information
| REO 016 | Intravenous administration in combination with paclitaxel and carboplatin | Phase II non-small cell lung cancer | U.S. | Ongoing |
| REO 015 | Intravenous administration in combination with paclitaxel and carboplatin | Phase II head and neck | U.S. | Ongoing |
| REO 014 | Intravenous administration monotherapy | Phase II sarcomas | U.S. | Ongoing |
| REO 013 | Intravenous administration monotherapy (sponsored by University of Leeds) | Translational metastatic colorectal | U.K. | Ongoing |
| NCI Trial | Intravenous administration monotherapy (NCI) | Phase II melanoma | U.S. | Ongoing |
| NCI Trial | Intravenous and intraperitoneal administration monotherapy (NCI) | Phase I/II ovarian | U.S. | Ongoing |
| REO 012 | Intravenous administration in combination with cyclophosphamide | Advanced malignancies including pancreatic, lung, ovarian | U.K. | Ongoing |
REO 011
(Phase II) | Intravenous administration in combination with paclitaxel and carboplatin | Phase II head and neck | U.K. | Ongoing |
| REO 011 | Intravenous administration in combination with paclitaxel and carboplatin | Advanced malignancies including melanoma, lung, ovarian | U.K. | Ongoing |
| REO 010 | Intravenous administration in combination with docetaxel | Advanced malignancies including bladder, prostate, lung, upper gastro-intestinal | U.K. | Complete |
| REO 009 | Intravenous administration in combination with gemcitabine | Advanced malignancies including pancreatic, lung, ovarian | U.K. | Complete |
| REO 008 | Local therapy in combination with radiation | Phase II various metastatic tumours, including head & neck | U.K. | Complete |
| REO 007 | Infusion monotherapy | Phase I/II recurrent malignant gliomas | U.S. | Ongoing |
| REO 006 | Local therapy in combination with radiation | Phase I various metastatic tumours | U.K. | Complete |
| REO 005 | Intravenous administration monotherapy | Phase I various metastatic tumours | U.K. | Complete |
| REO 004 | Intravenous administration monotherapy | Phase I various metastatic tumours | U.S. | Complete |
| REO 003 | Local monotherapy | Phase I recurrent malignant gliomas | Canada | Complete |
| REO 002 | Local monotherapy | T2 prostate cancer | Canada | Complete |
| REO 001 | Local monotherapy | Phase I trial for various subcutaneous tumours | Canada | Complete |